Patent ID: 11964016
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 65:
66. The method of claim 34, wherein:
the IL-4/IL-13 pathway inhibitor is an anti-IL-4R antibody, wherein the anti-IL-4R antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:1 and an LCVR comprising the amino acid sequence of SEQ ID NO:2; and
the anti-BCMA/anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises (a) a first antigen-binding domain that comprises an HCVR comprising the amino acid sequence of SEQ ID NO:12 and an LCVR comprising the amino acid sequence of SEQ ID NO:20; and a second antigen-binding domain that comprises an HCVR comprising the amino acid sequence of SEQ ID NO:36 and an LCVR comprising the amino acid sequence of SEQ ID NO:20.